Ippei Matsumoto

Dr. Ippei Matsumoto

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Pancreatology
Verified
Journal Article
Closed access
IMIppei Matsumoto
Ippei Matsumoto
YMYoshiaki Murakami
Yoshiaki Murakami
MSMakoto Shinzeki
Makoto Shinzeki
SASadaki Asari
Sadaki Asari
TGTadahiro Goto
Tadahiro Goto
YKYonson Ku
Yonson Ku

16 April 2025 in Annals of Surgery
Verified
Journal Article
Open access
MUMichiaki Unno
Michiaki Unno
FMFuyuhiko Motoi
Fuyuhiko Motoi
YMYutaka Matsuyama
Yutaka Matsuyama
Sohei SatoiSohei Satoi
Sohei Satoi
HTHirochika Toyama
Hirochika Toyama
TKTomoo Kosuge
Tomoo Kosuge
Objective: This randomized phase II/III study evaluated the superiority of neoadjuvant therapy with gemcitabine plus S-1 over upfront surgery for patients with resectable pancreatic ductal adenocarcinoma (PDAC). Background: PDAC is a leading cause of cancer mortality that urgently requires better treatment. Methods: Patients with resectable PDAC (without arterial abutment) were randomly assigned to upfront surgery or neoadjuvant chemotherapy with gemcitabine (1000 mg/m 2 days 1 and 8) and S-1 (40–60 mg orally twice daily, days 1–14 every 3 wk for 2 cycles). Phase II and III primary endpoints were resection rate and overall survival, respectively. UMIN Clinical Trials Registry number: UMIN000009634. Results: Patients (n=364) were enrolled and randomly allocated to upfront surgery (UPS; n=182) or neoadjuvant gemcitabine plus S-1 (NAC-GS; n=182). Patient demographics and tumor characteristics were balanced between groups. Median overall survival in the UPS and NAC-GS groups was 26.6 (95% CI: 21.5, 31.5) and 37.0 (95% CI: 28.6, 43.3) months, respectively. The hazard ratio for mortality in the NAC-GS group compared with the UPS group was 0.73 (95% CI: 0.56, 0.95; P =0.018). Median relapse-free survival in the UPS and NAC-GS groups was 11.3 (95% CI: 9.41, 13.5) and 14.3 (95% CI: 11.7, 17.0) months, respectively. The hazard ratio for relapse in the NAC-GS group compared with the UPS group was 0.77 (95% CI: 0.61, 0.98; P =0.030). Conclusions: The Prep-02/JSAP05 trial results showed that neoadjuvant chemotherapy with gemcitabine plus S-1 significantly extends survival compared with upfront surgery in patients with resectable PDAC.

21 March 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
F(for the Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS)
for the Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS)
SAShuichi Aoki
Shuichi Aoki
FMFuyuhiko Motoi
Fuyuhiko Motoi
YMYoshiaki Murakami
Yoshiaki Murakami
MSMasayuki Sho
Masayuki Sho
MUMichiaki Unno
Michiaki Unno
Carbohydrate antigen (CA) 19–9 levels after resection are considered to predict prognosis; however, the significance of decreased CA19–9 levels after neoadjuvant therapy has not been clarified. This study aimed to define the prognostic significance of decreased CA19–9 levels after neoadjuvant therapy in patients with pancreatic adenocarcinoma. Between 2001 and 2012, 240 consecutive patients received neoadjuvant therapy and subsequent resection at seven high-volume institutions in Japan. These patients were divided into three groups: Normal group (no elevation [≤37 U/ml] before and after neoadjuvant therapy), Responder group (elevated levels [> 37 U/ml] before neoadjuvant therapy but decreased levels [≤37 U/ml] afterwards), and Non-responder group (elevated levels [> 37 U/ml] after neoadjuvant therapy). Analyses of overall survival and recurrence patterns were performed. Uni- and multivariate analyses were performed to clarify the clinicopathological factors influencing overall survival. The initial metastasis sites were also evaluated in these groups. The Responder group received a better prognosis than the Non-responder group (3-year overall survival: 50.6 and 41.6%, respectively, P = 0.026), but the prognosis was comparable to the Normal group (3-year overall survival: 54.2%, P = 0.934). According to the analysis of the receiver operating characteristic curve, the CA19–9 cut-off level defined as no elevation after neoadjuvant therapy was ≤103 U/ml. The multivariate analysis revealed that a CA19–9 level ≤ 103 U/ml, (P = 0.010, hazard ratio: 1.711; 95% confidence interval: 1.133–2.639), tumor size ≤27 mm (P = 0.040, 1.517; (1.018–2.278)), a lack of lymph node metastasis (P = 0.002, 1.905; (1.276–2.875)), and R0 status (P = 0.045, 1.659; 1.012–2.627) were significant predictors of overall survival. Moreover, the Responder group showed a lower risk of hepatic recurrence (18%) compared to the Non-responder group (31%), though no significant difference in loco-regional, peritoneal or other distant recurrence were observed between groups (P = 0.058, P = 0.700 and P = 0.350, respectively). Decreased CA19–9 levels after neoadjuvant therapy predicts a better prognosis, with low incidence of hepatic recurrence after surgery.

1 July 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
KYKentaro Yamao
Kentaro Yamao
Mamoru TakenakaMamoru Takenaka
Mamoru Takenaka
RIRei Ishikawa
Rei Ishikawa
AOAyana Okamoto
Ayana Okamoto
TYTomohiro Yamazaki
Tomohiro Yamazaki
Masatoshi KudoMasatoshi Kudo
Masatoshi Kudo
Background: This study aimed to evaluate and identify the specific CT findings by focusing on abnormalities in the main pancreatic duct (MPD) and pancreatic parenchyma in patients with small pancreatic cancer (PC) including carcinoma in situ (CIS). Methods: Nine CT findings indicating abnormalities of MPD and pancreatic parenchyma were selected as candidate findings for the presence of small PC ≤ 10 mm. The proportions of patients positive for each finding were compared between small PC and benign MPD stenosis groups. Interobserver agreement between two independent image reviewers was evaluated using kappa statistics. Results: The final analysis included 24 patients with small PC (including 11 CIS patients) and 28 patients with benign MPD stenosis. The proportion of patients exhibiting partial pancreatic parenchymal atrophy (PPA) corresponding to the distribution of MPD stenosis (45.8% vs. 7.1%, p < 0.01), upstream PPA arising from the site of MPD stenosis (33.3% vs. 3.6%, p = 0.01), and MPD abrupt stenosis (45.8% vs. 14.3%, p = 0.03) was significantly higher in the small PC group than in the benign MPD stenosis group. Conclusions: The presence of partial PPA, upstream PPA, and MPD abrupt stenosis on a CT image was highly suggestive of the presence of small PCs including CIS.

7 November 2016 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
YNYoshihide Nanno
Yoshihide Nanno
IMIppei Matsumoto
Ippei Matsumoto
YZYoh Zen
Yoh Zen
KOKyoko Otani
Kyoko Otani
JUJun Uemura
Jun Uemura
YKYonson Ku
Yonson Ku

25 September 2023 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Open access
TSTeiichi Sugiura
Teiichi Sugiura
HTHirochika Toyama
Hirochika Toyama
AFAkira Fukutomi
Akira Fukutomi
HAHirofumi Asakura
Hirofumi Asakura
YTYuriko Takeda
Yuriko Takeda
KUKatsuhiko Uesaka
Katsuhiko Uesaka
Objective: The aim of the present study was to investigate which treatment, neoadjuvant chemoradiotherapy (NAC‐RT) with S‐1 or combination neoadjuvant chemotherapy with gemcitabine and S‐1 (NAC‐GS), is more promising as neoadjuvant treatment (NAT) for resectable pancreatic cancer in terms of effectiveness and safety.Methods: In the NAC‐RT with S‐1 group, the patients received a total radiation dose of 50.4 Gy in 28 fractions with oral S‐1. In the NAC‐GS group, the patients received intravenous gemcitabine at a dose of 1000 mg/m2 with oral S‐1 for two cycles. The primary endpoint was the 2‐year progression‐free survival (PFS) rate. The trial was registered with the UMIN Clinical Trial Registry as UMIN000014894.Results: From April 2014 to April 2017, a total of 103 patients were enrolled. After exclusion of one patient because of ineligibility, 51 patients were included in the NAC‐RT with S‐1 group, and 51 patients were included in the NAC‐GS group in the intention‐to‐treat analysis. The 2‐year PFS rate was 45.0% (90% confidence interval [CI]: 33.3%–56.0%) in the NAC‐RT with S‐1 group and 54.9% (42.8%–65.5%) in the NAC‐GS group (p = .350). The 2‐year overall survival rate was 66.7% in the NAC‐RT with S‐1 group and 72.4% in the NAC‐GS group (p = .300). Although leukopenia and neutropenia rates were significantly higher in the NAC‐GS group than in the NAC‐RT with S‐1 group (p = .023 and p < .001), other adverse events of NAT and postoperative complications were comparable between the two groups.Conclusion: Both NAC‐RT with S‐1 and NAC‐GS are considered promising treatments for resectable pancreatic cancer.